atovaquone
(Atovaquone)Bionpharma Inc.
Usage: Atovaquone oral suspension is indicated for the prevention and treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Its efficacy in severe cases or in patients failing TMP-SMX therapy is not established.